Stongbridge Biopharma to be acquired by Xeris Pharmaceuticals
Irish company valued at $267 million ahead of buyout by American pharma firm
Xeris Pharmaceuticals, the US pharma company with a market cap of $217 million, announced it is to acquire Stongbridge Biopharma, the Irish public limited company.
As part of the deal, Strongbridge has been valued at $267 million.
The merger aims to create a leading company in endocrinology and rare diseases with a pipeline of drug development. Strongbridge develops and commercialises therapies for people with rare diseases and significant unmet needs.
Subscribe from just €1 for the first month!
With any subscription you will have access to
Unlimited multi-device access to our iPad, iPhone and Android Apps
Unlimited access to our eReader library
Exclusive daily insight and opinion seven days a week
Create alerts to never miss a subject that matters to you
Get access to exclusive offers for subscribers on gifts and experiences
Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine
Irish arm of Otterbox ‘significantly outperformed’ expectations last year as revenues reached €46m
Phone case manufacturer employs 70 people at its European headquarters in Cork
‘It has been hectic. This event is our Super Bowl. There’s a non-stop stream of people’
Atmosphere of relief and excitement at AWS ReInvent
Out of Office: Omicron variant confirmed in Ireland; An Post eliminates gender pay gap
Your essential round-up of the latest business news
Turnover down 38% at Airbnb’s Irish unit as Covid hits revenue
Company, which has its European headquarters in Dublin, said business ‘declined significantly’ in early 2020 due to the pandemic